ContraFect initiated expanded access to Exebacase for treatment of MRSA bloodstream infections in COVID-19 patients
On Oct. 26, 2020, ContraFect announced that it had initiated an expanded access program to provide exebacase for…
-
-
Global clinical trials of COVID-19 vaccine resumed
On Oct. 23, 2020, the U.S. FDA authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford…
-
FDA approved first treatment for COVID-19
On Oct. 22, 2020, the FDA approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric…
-
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
-
Biotechnology | COVID-19 | FDA | Therapeutics
FDA approved Gilead’s antiviral Veklury (remdesivir) for treatment of COVID-19
On Oct. 22, 2020, Gilead Sciences announced that the FDA had approved the antiviral drug Veklury (remdesivir) for…
-
FDA authorized phase 1 trial of ImmunityBioﾒs novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
-
Tevogen Bio submitted IND for T cell treatment in COVID-19
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
-
Regeneron’s antibody cocktail REGN-EB3 (Inmazeb) first FDA-approved treatment for Ebola (Zaire Ebolavirus)
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
-
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
-
Vaxart announced positive hamster challenge study data for its oral COVID-19 vaccine
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyﾒs Investigational New…
-
Roche launched laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
On Oct. 13, 2020, Roche announced that it intended to launch a high-volume SARS-CoV-2 Antigen test as an…
-
New CAR T-Cell therapy approved and available at Roswell Park for lymphoma patients
On Oct. 13, 2020, Roswell Park Comprehensive Cancer Center announced that it had been approved to administer the…
-
FDA awarded grants to fund clinical trials to advance development of products for treatment of rare diseases
On Oct. 8, 2020, the FDA announced that it had awarded six new clinical trial research grants to…
-
Biotechnology | COVID-19 | Diagnostics | FDA
Abbott’s released ID NOW COVID-19 interim clinical study results to provide facts on clinical performance
On Oct. 7, 2020, in a continuing effort to provide the facts about ID NOW to support public…
-
FDA broadly supported Oragenicsﾒ pre-IND development program for its SARS-CoV-2 vaccine
On Oct. 6, 2020, Oragenics announced receipt of feedback to its Type B Pre-IND Meeting Request from the…
-
FDA amended EUA for Hologicﾒs Aptima SARS-CoV-2 assay to Include COVID-19 testing of asymptomatic individuals
On Oct. 6, 2020, Hologic announced that its Aptimaﾮ SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA)…
-
FDA awarded contract to Stanford University to perform in-depth analysis of tissue samples to learn how SARS-CoV-2 causes COVID-19
On Oct. 5, 2020, the FDA awarded a research contract to the Stanford University School of Medicine to…
-
Data from Corvus phase 1 study of CPI-006 continued to support its potential as treatment for COVID-19
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
FDA approved drug combination for treating mesothelioma
On Oct. 1, 2020, the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment…
-
LabCorp COVID-19 molecular test innovation received FDA authorization
On Oct. 2, 2020, LabCorp announced that it had received an Emergency Use Authorization (EUA) from the FDA…
-
Oxford Immunotec announced FDA clearance of the T-SPOT.TB test for use in pediatrics over the age of two
On Sept. 29, 2020, Oxford Immunotec announced that it had received clearance from the FDA to amend the…
-
Windtree announced FDA acceptance of IND application for phase 2 clinical trial studying KL4 Surfactant in acute lung injury in adults with COVID-19
On Sept. 29, 2020, Windtree Therapeutics announced that FDA had accepted its Investigational New Drug application for a…
-
Biotechnology | COVID-19 | FDA | Infectious Disease | NIH | Vaccine
INOVIO reported FDA partial clinical hold for planned phase 2/3 trial of COVID-19 vaccine candidate INO-4800
On Sept. 28, 2020, INOVIO announced the U.S. Food and Drug Administration (FDA) had notified the company that…
-
Hologic granted FDA Emergency Use Authorization for asymptomatic COVID-19 testing with Panther Fusion SARS-CoV-2 assay
On Sept. 28, 2020, Hologic announced that its Panther Fusionﾮ SARS-CoV-2 assay had received Emergency Use Authorization (EUA)…
-
FDA took actions to help lower US prescription drug prices
On Sept. 24, 2020, the U.S. Department of Health and Human Services and the U.S. Food and Drug…
-
FDA authorized first point-of-care antibody test for COVID-19
On Sept. 23, 2020, the FDA issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care…
-
FDA launched the Digital Health Center of Excellence
On Sept. 22, 2020, the FDA announced it had launched the Digital Health Center of Excellence within the…
-
Roche launched new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
On Sept. 18, 2020, Roche announced the launch of its Elecsysﾮ Anti-SARS-CoV-2 S antibody test for markets accepting…
-
COVID-19 | FDA | Therapeutics
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
-
FDA contracted with global partners to analyze coronavirus samples
On Sept. 15, 2020, the FDA awarded a $5.4 million research contract to the University of Liverpool and…
